S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

DTIL Precision BioSciences Inc

7.26

-0.36 (-4.72%)

Nov 18 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Precision BioSciences Charts.

Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Precision BioSciences Charts.

Precision BioSciences Inc News

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Friday 15 November 2024 (4 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Monday 4 November 2024 (2 weeks ago) • Business Wire

Precision BioSciences to Report Third Quarter Results on November 4, 2024
Tuesday 29 October 2024 (3 weeks ago) • Business Wire

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Monday 28 October 2024 (3 weeks ago) • Business Wire

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Thursday 24 October 2024 (4 weeks ago) • Business Wire

More Precision BioSciences Inc News Articles

Elite Pharmaceuticals (QB)

North Bay Resources (PK)

Halozyme Therapeutics

Sincerity Applied Materi... (PK)

TPT Global Tech (PK)

Super Micro Computer

Voip Pal Com (QB)

Intergrated Cannabis Sol... (PK)

Global Developments (PK)

Enzolytics (PK)

Net Savings Link (PK)

Decentral Life (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions